Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 297

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Blood (2024) 144 (Supplement 1): 733.

https://doi.org/10.1182/blood-2024-209097

Published: 2024

Journal Articles

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Blood (2024) 144 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2024-201317

Published: 2024

Journal Articles

Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Sylvain Garciaz, Rémy Castellano, Arnaud Jacquel, Arnaud Guille, Maxence Bourgoin, Camille Montersino, José Adélaïde, Patrick Auberger, Daniel Birnbaum, Marie Anne Hospital, Yves Collette, Norbert Vey

Blood (2024) 144 (Supplement 1): 1378.

https://doi.org/10.1182/blood-2024-207352

Published: 2024

Journal Articles

Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Sylvain Garciaz, Pierre Bories, Jean-Marie Boher, Marie Anne Hospital, Christian Récher, Colombe Saillard, Yosr Hicheri, Renato Monteiro, Olivier Hermine, Pierre Launay, Norbert Vey

Blood (2024) 144 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2024-207436

Published: 2024

Journal Articles

Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Pierre-Yves Dumas, Sarah Bertoli, Clémence Santana, Mael Heiblig, Thibaut Leguay, Suzanne Tavitian, Eric Delabesse, Émilie Klein, Emmanuelle Tavernier, Martin Carre, Gaspar Aspas Requena, Anne Banos, Norbert Vey, Arnaud Pigneux, Christian Récher, Sylvain Garciaz

Blood (2024) 144 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2024-210596

Published: 2024

Journal Articles

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Blood (2023) 142 (Supplement 1): 4261.

https://doi.org/10.1182/blood-2023-173656

Published: 2023

Journal Articles

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Thibault Comont, Olivier Kosmider, Mael Heiblig, Benjamin Terrier, Didier Bouscary, Guillaume Le Guenno, Roderau Outh, Maxime Samson, Achille Aouba, Estibaliz Lazarro, Odile Rauzy, Lucie Rigolot, Pierre Peterlin, Alexandre Maria, Edouard Flammarion, Alice Garnier, Benoit De Renzis, Shanti Natarajan, Benjamin Carpentier, Marielle Roux-Sauvat, Jose Torregrosa, Fabienne Closs-Prophette, Julien Rossignol, Nicolas Schleinitz, Celine Dieval, Jonahan Broner, Marie-Pierre Gourin, Gaetan Sauvetre, Benoit Faucher, Julien Vinit, Sylvie Grosleron, Alexis Mathian, Louis Terriou, Cyrille Coustal, Philippe Guilpain, Paola Marianetti-Guingel, Holy Bezanahary, Norbert Vey, Bilal Mohty, Thomas Moulinet, Vincent Grobost, Sophie Dimicoli, Benoit Suzon, Antoinette Perlat, Pierre Hirsh, Lise Larcher, Lin Pierre Zhao, Sophie Georgin-Lavialle, Arsene Mekinian, Pierre Fenaux, Vincent Jachiet, French VEXAS study group, Minhemon French Network of immune disorders associated with hemopathies, GFM Groupe Francophone des Myélodysplasies

Blood (2023) 142 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2023-178125

Published: 2023

Journal Articles

Evaluation of ICT01, a γ9δ2 T Cell-Activating Monoclonal Antibody, Combined with Venetoclax and Azacitidine in 1L AML (EVICTION Study)

Elisabeth Wieduwild, Anne-Charlotte Le Floch, Céline Garulli, Caroline Imbert, Aude De Gassart, Patrick Brune, Katrien Lemmens, Sylvain Garciaz, Abhishek Maiti, Pierre Peterlin, Celine Leparquier, Marina Iche, Norbert Vey, Daniel Olive, Paul Frohna

Blood (2023) 142 (Supplement 1): 1552.

https://doi.org/10.1182/blood-2023-189936

Published: 2023

Journal Articles

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2023) 142 (Supplement 1): 967.

https://doi.org/10.1182/blood-2023-179376

Published: 2023

Journal Articles

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Blood (2023) 142 (Supplement 1): 6483.

https://doi.org/10.1182/blood-2023-186086

Published: 2023

Journal Articles

CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2023-184591

Published: 2023

Journal Articles

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Blood (2023) 142 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2023-177951

Published: 2023

Journal Articles

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Blood (2023) 142 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2023-180733

Published: 2023

Journal Articles

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A Sallman, Justine Decroocq, Pierre-Yves Dumas, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Ludovic Gabellier, Marie Anne Hospital, Ariane Mineur, Arnaud Pigneux, Norbert Vey, Christian Récher

Blood (2023) 142 (Supplement 1): 161.

https://doi.org/10.1182/blood-2023-185437

Published: 2023

Journal Articles

Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Sylvain Garciaz, Pierre Bories, Jean-Marie Boher, Marie Anne Hospital, Christian Récher, Colombe Saillard, Yosr Hicheri, Coralie Belanger, Renato Monteiro, Olivier Hermine, Pierre Launay, Norbert Vey

Blood (2023) 142 (Supplement 1): 4290.

https://doi.org/10.1182/blood-2023-185717

Published: 2023

Journal Articles

Efficacy of Chemo-Free Combination Therapy with BRAF Inhibitor and Rituximab in Classic Hairy Cell Leukemia: Insights from the French Experience

Luca Inchiappa, Lise Willems, Jérôme Paillassa, Charles Herbaux, Cecile Tomowiak, Anne Lok, Diane Lara, Bijou Fontanet, Urbain Tauveron-Jalenques, Antoine Ittel, Adrien Caillet, Norbert Vey, Xavier Troussard

Blood (2023) 142 (Supplement 1): 6170.

https://doi.org/10.1182/blood-2023-186971

Published: 2023

Journal Articles

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Blood (2023) 141 (11): 1265–1276.

https://doi.org/10.1182/blood.2022016362

Published: 2023

Includes: Supplemental data

Journal Articles

Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study

Blood (2022) 140 (Supplement 1): 6142–6144.

https://doi.org/10.1182/blood-2022-167000

Published: 2022

Journal Articles

Autologous Stem Cell Transplant in 2 nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

Blood (2022) 140 (Supplement 1): 7712–7713.

https://doi.org/10.1182/blood-2022-158171

Published: 2022

Journal Articles

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Sylvain Garciaz, Yves Collette, Remy Castellano, Michel Aurrand-Lions, Helene Sicard, Laetitia Jentreau, Norbert Vey, Cecile Bougeret

Blood (2022) 140 (Supplement 1): 7800–7801.

https://doi.org/10.1182/blood-2022-166820

Published: 2022

NARROW

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Evaluation of ICT01, a γ9δ2 T Cell-Activating Monoclonal Antibody, Combined with Venetoclax and Azacitidine in 1L AML (EVICTION Study)

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Efficacy of Chemo-Free Combination Therapy with BRAF Inhibitor and Rituximab in Classic Hairy Cell Leukemia: Insights from the French Experience

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study

Autologous Stem Cell Transplant in 2 nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only